Stay up to date with our newsletter

Get in touch!

What can we do to help?

I would like to:

Lets start the conversation!

Sign up to our newsletter

View open positions on our Careers page,
or connect with us on Linkedin Twitter Facebook

Thank you!
We will be in touch shortly.

2020.05.07

Sai Life Sciences joins the global ‘COVID Moonshot’ project

Sai Life Sciences, today announced its collaboration with the COVID Moonshot project that aims to deliver an antiviral drug candidate effective against COVID-19. With an in-kind contribution of a team of Medicinal Chemists and supporting infrastructure, Sai Life Sciences will help synthesize and profile analogues for NCEs and other previously known compounds tested for other viruses.

PostEra, a biotechnology company specialising in machine learning for drug discovery, is leading the initiative. Joining them are leading experts in the fields of computational drug discovery, chemical synthesis and biochemical assays. In the three months since its start in February this year, the team has already identified over 60 experimentally-confirmed ‘fragments’ that effectively target a key protein associated with COVID-19. It has now opened a crowdsourcing initiative to accelerate the design of potential drug candidates from these fragments and received over 4000 submissions from contributors around the world.

Welcoming Sai Life Sciences into the consortium, CEO of PostEra Aaron Morris, said, "We are immensely grateful for Sai Life Sciences’ contribution to this project. They are helping take the most promising crowdsourced ideas from the Moonshot platform and turning these ideas into chemical reality. It is generosity like this that gives us hope that this moonshot of a project could achieve something ground-breaking in our search for an effective COVID antiviral.”

Speaking about its participation in the project, CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri said, “We are delighted to join this important global initiative. The consortium approach to finding treatments for patients in the fight against COVID-19 is a worthy cause and something that aligns very well with our purpose of working with partners to accelerate solutions for improving life.”

Over the past two decades, Sai Life Sciences has built up a portfolio of NCE Discovery services on the foundation of a strong chemical synthesis platform. The company today offers innovator biotechs and pharmaceutical companies the full spectrum of Discovery services from Target ID & Validation through till IND, in addition to a robust suite of capabilities across NCE development and cGMP manufacturing.

News

2020.04.11

AAALAC full accreditation

AAALAC International renews full accreditation to Sai Life Sciences for its laboratory animal care and use program

As a validation of our commitment to maintaining the highest standards in animal care and compliance with industry and regulatory guidelines, the Sai Life Sciences discovery facility in Pune recently received a renewed accreditation for its laboratory animal care and use program from AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care) International. […]
Read more

2020.04.02

Sai Life Sciences becomes first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI)

Sai Life Sciences becomes first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI)

Sai Life Sciences, today announced its induction into the Pharmaceutical Supply Chain Initiative (PSCI) membership as an ‘Associate Member’. Welcoming Sai Life Sciences into its fold, a PSCI spokesperson said, “PSCI and its members are delighted to welcome Sai Life Sciences into membership, PSCI’s first member with its main headquarters in India. We are pleased […]
Read more

2020.04.01

Making sanitizers available during COVID-19 outbreak

Making sanitizers available during COVID-19 outbreak

Over the past few weeks since the outbreak of COVID-19, there’s been a sudden rise in sanitization efforts by various public and private organizations to help arrest the spread of the disease. This, along with efforts of individuals in their own spaces, has created a huge demand for effective alcohol-based sanitizers to aid the sanitization […]
Read more

2020.03.02

ISO 14001:2015 & ISO 45001:2018

Sai Life Sciences receives ISO 14001:2015 and ISO 45001:2018 certification

Sai Life Sciences received the ISO 14001:2015 (Environment management system) and ISO 45001:2018 (Occupational health and safety management system) certification for its R&D centre (Unit II), Manufacturing facility (Unit IV) and Corporate office. Certified by Bureau Veritas, it reflects the organization’s commitment towards continually improving its health, safety & environment performance. Responding to the development, […]
Read more

2020.02.25

2nd SCMPro India Procurement Leadership Forum & Awards 2020

Sai Life Sciences SCM shines with awards in Supply Risk and Supplier Relationship Management

Sai Life Sciences won two awards at the recently concluded 2nd SCMPro India Procurement Leadership Forum & Awards 2020, in the categories of Supply Risk Management and Supplier Relationship Management. The awards were selected by a panel of eminent academicians and industry leaders to recognize organizations and individuals who exhibit outstanding approaches in creating compliant […]
Read more